Already popular in the analysis of medical device trials, adaptive Bayesian designs are increasingly being used in drug development for a wide variety of diseases and conditions, from Alzheimer's disease and multiple sclerosis to obesity, diabetes, hepatitis C, and HIV. Written by leading pioneers of Bayesian clinical trial designs, Bayesian Adapti
Autorentext
Scott M. Berry is the President and Senior Statistical Scientist at Berry Consultants, a statistical consulting group specializing in adaptive clinical trial design in pharmaceutical and medical device research and development.
Bradley P. Carlin is Mayo Professor in Public Health and Head of the Division of Biostatistics at the University of Minnesota.
J. Jack Lee is Professor of Biostatistics at the University of Texas M.D. Anderson Cancer Center.
Peter Muller is a Robert R. Herring Distinguished Professor in Clinical Research in the Department of Biostatistics at the University of Texas M.D. Anderson Cancer Center.